MedTrace Logo

Biomarker and Genetic Predictors of Erenumab Treatment Response

NCT04265755 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 1406

Last updated 2024-06-07

Study results available
· View outcomes & findings →

Summary

To explore the relationship between clinical response to erenumab and genetic biomarkers

Conditions

Interventions

DRUG

Erenumab

Erenumab 70 mg or 140 mg packed in a SureClick® Autoinjector Pen (AI).

Sponsors & Collaborators

Principal Investigators

  • MD · Amgen

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-26
Primary Completion
2023-01-18
Completion
2023-01-18

Countries

  • Denmark
  • Iceland

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04265755 on ClinicalTrials.gov